GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » Total Long-Term Assets

HBM Holdings (FRA:6XY) Total Long-Term Assets : €18.07 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. HBM Holdings's Total Long-Term Assets for the quarter that ended in Dec. 2024 was €18.07 Mil.


HBM Holdings Total Long-Term Assets Historical Data

The historical data trend for HBM Holdings's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Total Long-Term Assets Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
Get a 7-Day Free Trial 15.98 36.72 21.82 16.79 18.07

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.82 18.90 16.79 15.62 18.07

HBM Holdings Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


HBM Holdings Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

HBM Holdings Headlines

No Headlines